Traditional targeting? What' novel?

Hot news! GSK and Yale to work on new class of medicines! I am very interested to know what it is.

UK drug giant GlaxoSmithKline has hooked up with Yale University under a collaboration that will focus on designing a potential new class of medicines.

For sure! And what is it?

Under the discovery pact, GSK scientists are putting their heads together with Yale researchers to build on the latter's pioneering work with so-called proteolysis targeting chimeric molecules (PROTACs).

Mutant or unusually high levels of these proteins can be linked with disease progression in a number of areas, such as oncology and inflammation, but as yet cannot be tackled by traditional ways of making drugs, GSK notes.

Well, it is enough. Just the same “targeting” approach which is still sexy for pharmaplankton .

With GSK's expertise in medicinal chemistry the joint research team is hoping to have proof-of-principle data in the bag by the end of this year, paving the way for development of the technology into future medicines.

Let us see what results will be published (if any) to the end of the year!